Document is current
Any future updates will be listed below
-
Authors
Zysman, M. https://orcid.org/0000-0001-7183-9987
Rubenstein, J.
Le Guillou, F.
Colson, R. M. H.
Pochulu, C.
Grassion, L.
Escamilla, R.
Piperno, D.
Pon, J.
Khan, S.
Raherison-Semjen, C.
-
Funding
Funding for this research was provided by:
AstraZeneca
Chiesi
SOS oxygène
GSK
Novartis
Philips Healthcare
- License Information
-
More Information
Article History
Received: 10 March 2020
Accepted: 12 November 2020
First Online: 25 November 2020
Ethics approval and consent to participate
: Study protocol has been approved by the Ethics Committee of Versailles Saint Quentin University.
: All patients provided written consent. All authors provided consent to publication.
: JR has nothing to disclose. MZ reports grants and personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from Chiesi, and personal fees from GSK outside the submitted work. FLG has nothing to disclose. CP has nothing to disclose. LG reports grants and personal fees from SOS oxygène. RE has nothing to disclose. DP has nothing to disclose. PJ has nothing to disclose. CRS reports grants and personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from Chiesi, and personal fees from GSK outside the submitted work.
